CTRI/2010/091/001098已完成3 期
Phase III randomized trial of BIBW 2992 plus weekly paclitaxel versus Investigator?s choice of chemotherapy following BIBW 2992 monotherapy in non-small cell lung cancer patients failing previous erlotinib or gefitinib treatment
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Pathologically confirmed diagnosis of NSCLC Stage IIIb (with cytologically proven pleural effusion or pericardial effusion) or Stage IV who have failed treatment with erlotinib (Tarceva®) or gefitinib (Iressa®).
- •2. Received and failed at least one line of cytotoxic chemotherapy including a platinum-based regimen in patients eligible for platinum-based therapy for advanced or metastatic disease.
- •a. Known EGFR mutation shown by accepted methods are eligible after therapy with reversible TKI without prior chemotherapy.
- •b. Clinical benefit (disease stabilization or anti-tumour response) toerlotinib (Tarceva®) or gefitinib (Iressa®) for ≥6 months are eligiblewithout prior chemotherapy.
- •3. Eastern Cooperative Oncology Group (ECOG) performance Score 0-2
- •4. At least one tumour lesion that can accurately be measured by magnetic resonance imaging (MRI), or computed tomography (CT) in at least one dimension with longest diameter to be recorded as ≥20 mm using conventional techniques or ≥10 mm with spiral CT scan according to RESIST 1.1.
- •5.Male or female age ≥18 Years.
- •6.Life expectancy of at least 12 weeks
- •7.Written informed consent that is consistent with ICH-GCP guidelines.
排除标准
- •1. Previous treatment with BIBW 2992
- •2. Chemo-, hormone- (other than corticosteroids required for maintenance non-cancer therapy or as premedication before chemotherapy) or immunotherapy within the past 4 weeks, for pretreatment with TKIs (erlotinib (Tarceva®) or gefitinib (Iressa®)) 2 weeks only.
- •3. Active brain metastases (stable <4 weeks, symptomatic, or leptomeningeal disease. Dexamethasone therapy will be allowed if administered as a stable dose for at least one month before randomization.
- •4. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn?s disease, mal-absorption, or CTCAE Grade >2 diarrhea of any etiology at baseline.
- •5. Any other life-threatening illness or organ system dysfunction, which in the opinion of the Investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug.
- •6. Other malignancies diagnosed (other than non - melanomatous skin cancer and in situ cervical cancer) requiring therapy.
- •7. Radiotherapy within the past 2 weeks prior to treatment with the trial drug.
- •8. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) functional classification of 3, unstable angina, or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomization.
- •9. Cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogram.
- •10. Prior treatment with anthracyclines with a cumulative dose of doxorubicin (or equivalent) ≥400 mg/m2.
- •11. Absolute neutrophil count (ANC) ≤1500/mm3.
- •12.Platelet count ≤100,000/mm3.
- •13. Bilirubin ≥1.5 mg/dL (>26 μmol/L, SI unit equivalent)
- •14.Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≥ three times the upper limit of normal (if related to liver metastases ≥ five times the upper limit of normal).
- •15. Serum creatinine ≥1.5 times the upper normal limit or calculated/measured creatinine clearance ≤45 mL/min.
- •16. Women of child-bearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial.
- •17. Pregnancy or breast feeding.
- •18. Unable to comply with the protocol.
- •19. Any serious active infection including known human immunodeficiency virus (HIV), active hepatitis B or active hepatitis C.
- •20. Known or suspected active drug or alcohol abuse.
- •21. Pre-existing or current interstitial lung disease (ILD).
- •22. Peripheral polyneuropathy >Grade 2.
研究者
相似试验
进行中（未招募）
不适用
Phase III randomized trial of BIBW 2992 plus weekly paclitaxel versusInvestigator’s choice of chemotherapy following BIBW 2992monotherapy in non-small cell lung cancer patients failing previouserlotinib or gefitinib treatmentPatients with NSCLC stage IIIb and IV after failure of treatment with erlotinib or gefitinibEUCTR2009-014563-39-HUBoehringer Ingelheim Pharma GmbH & Co. KG1,100
进行中（未招募）
不适用
Phase III randomized trial of BIBW 2992 plus weekly paclitaxel versusInvestigator’s choice of chemotherapy following BIBW 2992monotherapy in non-small cell lung cancer patients failing previouserlotinib or gefitinib treatmentPatients with NSCLC stage IIIb and IV after failure of treatment with erlotinib or gefitinibEUCTR2009-014563-39-BESCS Boehringer Ingelheim Comm. V1,100
进行中（未招募）
1 期
X-Lung 5: BIBW 2992 (afatinib) plus weekly paclitaxel versus investigator's choice of single agent chemotherapy following BIBW 2992 monotherapy in non-small cell lung cancer patients failing erlotinib or gefitinibEUCTR2009-014563-39-GBBoehringer Ingelheim Limited1,302
进行中（未招募）
不适用
Phase III randomized trial of BIBW 2992 plus weekly paclitaxel versusInvestigator’s choice of chemotherapy following BIBW 2992monotherapy in non-small cell lung cancer patients failing previouserlotinib or gefitinib treatmentPatients with NSCLC stage IIIb and IV after failure of treatment with erlotinib or gefitinibEUCTR2009-014563-39-DEBoehringer Ingelheim Pharma GmbH & Co. KG1,100
进行中（未招募）
1 期
Phase III randomized trial of BIBW 2992 plus weekly paclitaxel versusInvestigator’s choice of chemotherapy following BIBW 2992monotherapy in non-small cell lung cancer patients failing previouserlotinib or gefitinib treatment - LuxLung 5Patients with NSCLC (non-small cell lung cancer) stage IIIb and IV experiencing a benefit from BIBW 2992 monotherapy after failing at least one line of chemotherapy and prior treatment with erlotinib or gefitinib.EUCTR2009-014563-39-FRBoehringer Ingelheim France900